Focus Area
Research & Science
The world is running low on new antibiotics, and the market is to blame.
Why the Antibiotic Pipeline Keeps Thinning
Payment systems still reward the volume of antibiotics sold rather than their value to society, so companies cannot sustain the investment that new medicines require, and the pipeline keeps thinning. The scientific workforce is thinning, too.
By the numbers
A Shrinking Workforce, a Steady Investment
01
researchers identified working on AMR
02
researchers working on cancer, by comparison
03
invested by Alliance members in AMR research and development each year
Sources: AMR Industry Alliance, Leaving the Lab, 2024; RAND Europe / AMR Industry Alliance Progress Survey.
Our Response
Rebuilding the Pipeline
Alliance members invest around $2 billion in AMR research and development each year, evidence that the private sector continues to invest even where incentives fall short.
We track the scale of the decline and support the pull incentives and de-linked payment models, such as subscription-style purchasing, that would reward responsible supply and rebuild the pipeline.
Featured Report
Leaving the Lab
An analysis of the scientific workforce working on antimicrobial resistance.
Resources
Explore Research & Science Resources
Access research, reports, and news on antimicrobial innovation and the scientific workforce working to address antimicrobial resistance.
A Personnel Problem: We Need More Antimicrobial Researchers, Infectious Disease Clinicians
Belgium Developing New Class of Antibiotics, But Incentives and Market Support Needed
Get in touch
Whether you’re a member, a partner, or exploring how to engage,
we’d like to hear from you.